…Thank you to all neurologists who completed the social media survey. The data are now being analysed by Dr. Jiwon Oh, University of Toronto, and an abstract of the results will be submitted for presentation at an upcoming international congress. COMING SOON… Part 2 of the social media survey. Watch for our announcement in an upcoming issue of NeuroSens….
…ed a phase II trial to evaluate the potential benefits of pioglitazone (NET-PD FS-ZONE Investigators. Lancet Neurol 2015;14:795-803). A total of 210 subjects with early PD and on a stable drug regimen (rasagiline 1 mg/day or selegiline 10 mg/day) were randomized to one of two doses of pioglitazone (15 or 45 mg/day) or placebo. The primary outcome was the change from baseline in the total UPDRS score at week 44. The null hypothesis was a mean UPDRS…
…6) (Kremenchutzky et al. AAN 2016; abstract P3.027). The proportion relapse-free during the extension was 51.5% and 39.5%, respectively. EDSS scores were stable. There were no new/unexpected adverse events. A prospective study evaluated brain volume change in 30 RRMS patients treated with teriflunomide and 20 healthy controls (Zivadinov et al. AAN 2016; abstract P3.062). At 12 months, the percent change in whole brain volume was -0.50% with terifl…
…older TBI patients were more likely to be diagnosed with PD over the next 5-7 years compared to non-TBI trauma patients (1.7% vs. 1.1%; adjusted HR 1.44). PD risk was similar in patients with TBI due to a fall compared to other TBI causes. PD risk was higher following moderate/severe TBI compared to mild TBI (HR 1.50 vs. 1.24), and was increased with more frequent TBIs (HR 1.87 for >1 TBI vs. 1.45 for 1 TBI). Also noteworthy is a recent case-contr…
…cid amide hydrolase (FAAH) inhibitor that was undergoing testing in a first-in-man phase I trial in Rennes, France. A total of 64 healthy volunteers aged 18-55 years participated in a single ascending dose stage to test eight doses (0.25 to 100 mg) versus placebo. This phase of the study ran from July 9 to October 9, 2015, with no significant toxicities reported. For the multiple ascending dose study that began on October 6, 48 healthy volunteers…